Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer

Asten, Kathleen Van; Slembrouck, Laurence; Olbrecht, Siel; Jongen, Lynn; Brouckaert, Olivier; Wildiers, Hans; Floris, Giuseppe; Limbergen, Erik; Weltens, Caroline; Smeets, Ann; Paridaens, Robert; Giobbie‐Hurder, Anita; Regan, Meredith M.; Viale, Giuseppe; Thürlimann, Beat; Vergote, Ignace; Christodoulou, Evangelia; Calster, Ben Van; Neven, Patrick

doi:10.1634/theoncologist.2018-0176

Cited by 34 publications

(34 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The initial search strategy identified 3900 articles, of which 51 full articles were deemed eligible for review. After application of inclusion and exclusion criteria, eight studies were selected for inclusion ( Fig . ).…”

Section: Resultsmentioning

confidence: 99%

“…Although it has been proposed that lack of PgR expression in tumours may indicate impaired growth factor signalling in areas such as the phosphatidylinositol 3‐kinase/Akt/mammalian target of rapamycin pathway, with resulting resistance to tamoxifen, at present PgR status is not considered to confer a selective advantage between EHT types and ER status remains the only factor predictive of tamoxifen benefit. In the present analysis, data relating to EHT in the ER+PgR– group were available in four of the eight studies, with a fifth study reporting that 95·3 per cent of all patients with ER+ tumours received EHT. In only one of these studies did less than 86 per cent of patients with ER+PgR– disease receive EHT, probably owing to the time period in which the patients were treated (1986–1998).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Meta-analysis of the impact of progesterone receptor status on oncological outcomes in oestrogen receptor-positive breast cancer

Boland

Ryan

Dunne

et al. 2020

Journal of British Surgery

View full text Add to dashboard Cite

Background: Assessment of the oestrogen receptor (ER) provides important prognostic information in breast cancer. The impact of progesterone receptor (PgR) status is less clear. Standardization of immunohistochemical analysis of these receptors has reduced interstudy heterogeneity. The aim of this meta-analysis was to evaluate the impact of PgR negativity on outcomes in ER-positive (ER+) breast cancer.Methods: This study was performed according to PRISMA and MOOSE guidelines. PubMed, Embase and the Cochrane Library were searched systematically to identify studies comparing disease-free survival as the primary outcome and overall survival as secondary outcome between PgR-positive (PgR+) and PgR-negative (PgR-) status in ER+ breast cancer. A meta-analysis of time-to-effect measures from included studies was undertaken.Results: Eight studies including 13 667 patients, 11 838 in the ER+PgR+ group and 1829 in the ER+PgR-group, met the inclusion criteria. Treatment characteristics did not differ significantly between the two groups. Patients in the ER+PgR-group had a higher risk of disease recurrence than those who had ER+PgR+ disease (hazard ratio (HR) 1⋅57, 95 per cent c.i. 1⋅38 to 1⋅79; P < 0⋅001). This hazard was increased in patients with human epidermal growth factor receptor 2-negative tumours (HR 1⋅62, 1⋅37 to 1⋅93; P < 0⋅001). A similar result was observed for overall survival (HR 1⋅69, 1⋅33 to 2⋅14; P < 0⋅001).Conclusion: PgR negativity is associated with significant reductions in disease-free and overall survival in ER+ breast cancer. Treatment and surveillance strategies in these patients should be tailored accordingly.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Meta-analysis of the impact of progesterone receptor status on oncological outcomes in oestrogen receptor-positive breast cancer

Boland

Ryan

Dunne

et al. 2020

Journal of British Surgery

View full text Add to dashboard Cite

show abstract

“…In recent years, several biomarkers including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), and proliferation marker Ki-67 have been used for prediction and treatment guidance of breast cancer. 7 Usually, ER-positive patients will benefit from hormonal therapy. Overexpression of HER2 is associated with more aggressive tumor type and poor clinical outcome.…”

Section: Introductionmentioning

confidence: 99%

High Prevalence of Triple-Negative Breast Cancer in Southern Shaanxi Province, China

Xing

Fan

Gao

et al. 2021

CMAR

View full text Add to dashboard Cite

Purpose Describing the clinical features of patients with breast cancer in an area is important to provide the information for the local oncologist to make sound treatment plans. In this study, we explored the clinical features of breast cancer patients in Southern Shaanxi Province, China. Patients and Methods A total of 328 breast cancer patients between 2010 and 2015 were recruited at our hospital. Patients’ clinical information and the results of the histopathological examination were collected. Independent sample t -test and Cox regression were used to analyze the data. Results The peak age onset of these patients was between 45 and 50. At diagnosis, 8.23% of patients were at clinical stage 1 and 29.57% were triple-negative breast cancer subtype. High expression of Ki-67 in these patients was found associated with triple-negative breast cancer. The 5-year survival rate in these patients was 66.4%, and the survival rate in stage 1 and 2 patients (88.2%) was significantly higher than that in stage 3 and4 (57.4%). Conclusion We here reported the clinical features of patients with breast cancer in Southern Shaanxi Province, China. The breast cancer patients in Southern Shaanxi Province showed a unique clinical feature.

show abstract

“…9 But some other data suggest that an AR agonist could play a role as a tumor suppressor. 13,14 Even if, in general, it seems preferable to refrain from giving any estrogenic or androgenic treatment, we considered the wish of our patient not to interrupt his supplementation. In our case, as a first step, CSH was pursued at one-half dose based on a multidisciplinary discussion.…”

Section: Discussionmentioning

confidence: 99%

Invasive Breast Cancer in a Trans Man After Bilateral Mastectomy: Case Report and Literature Review

Kopetti

Schaffer

Zaman

et al. 2021

Clinical Breast Cancer

View full text Add to dashboard Cite

Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer

Cited by 34 publications

References 38 publications

Meta-analysis of the impact of progesterone receptor status on oncological outcomes in oestrogen receptor-positive breast cancer

Meta-analysis of the impact of progesterone receptor status on oncological outcomes in oestrogen receptor-positive breast cancer

High Prevalence of Triple-Negative Breast Cancer in Southern Shaanxi Province, China

Invasive Breast Cancer in a Trans Man After Bilateral Mastectomy: Case Report and Literature Review

Contact Info

Product

Resources

About